A Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for COVID-19

- By Kailasam Saravana Mani1
-
View Affiliations Hide AffiliationsAffiliations: 1 Department of Chemistry, Karpagam Academy of Higher Education, Coimbatore – 641 021,Tamil Nadu, India
- Source: An Epidemiological Update on COVID-19 , pp 55-62
- Publication Date: July 2022
- Language: English
Research revealed that in vitro activity ofchloroquine and the derivative molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and chloroquine phosphate for the critical patients of COVID-19. The clinical trials supported that the hydroxychloroquine did not substantially reduce the system severity in non-hospitalized persons. Moreover, it also produces severe side effects like drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.
Hardbound ISBN:
9789815050332
Ebook ISBN:
9789815050325
-
From This Site
/content/books/9789815050325.chap7dcterms_subject,pub_keyword-contentType:Journal105
/content/books/9789815050325.chap7
dcterms_subject,pub_keyword
-contentType:Journal
10
5
Chapter
content/books/9789815050325
Book
false
en
